Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia
2025-04-16
عنوان الدراسة
Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia
داعم الدراسة
Novartis Saudi Ltd
دواء الدراسة
kisqaLi (ribociclib)
رقم بروتوكول الدراسة
CLEE011ASA
حالة الدراسة
Ongoing
موقع الدراسة
King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。